Edition:
India

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,445JPY
21 Sep 2017
Change (% chg)

¥-16 (-1.06%)
Prev Close
¥1,460
Open
¥1,466
Day's High
¥1,474
Day's Low
¥1,444
Volume
8,469,000
Avg. Vol
7,430,995
52-wk High
¥1,688
52-wk Low
¥1,332

Select another date:

Wed, Sep 20 2017

BRIEF-R&I affirms Astellas Pharma's rating at "AA" and says stable outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA"-R&I

CORRECTED-UPDATE 2-Pfizer, Astellas prostate cancer drug succeeds key trial

Sept 14 Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.

Pfizer, Astellas prostate cancer drug clears late-stage trial

Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal in a late-stage trial.

CORRECTED-Pfizer, Astellas prostate cancer drug clears late-stage trial

Sept 14 Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.

BRIEF-Astellas Pharma and Pfizer say positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide)

* Co and Pfizer Inc announced that the Phase 3 PROSPER trial evaluating XTANDI®(enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) CastrationResistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS)

BRIEF-Pfizer, Astellas report positive top-line results from phase 3 PROSPER trial of XTANDI

* Pfizer and Astellas announce positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide) in patients with non-metastatic castration-resistant prostate cancer

BRIEF-U.S. FDA accepts for review Astellas' supplemental NDA for mirabegron for use in combination with solifenacin succinate

* U.S. FDA accepts for review Astellas' supplemental New Drug Application for Mirabegron for use in combination with solifenacin succinate 5 mg for the treatment of overactive bladder

BRIEF-Astellas Pharma submits application for approval of fidaxomicin for the treatment of infectious enteritis in Japan

* Says it has submitted an application for marketing approval of fidaxomicin for the treatment of infectious enteritis in Japan

UPDATE 1-Japanese drugmaker Takeda posts stronger profit as U.S. sales jump

* Astellas Q1 operating profit halves from year ago (Adds wider industry context, Astellas results)

BRIEF- Astellas Pharma to repurchase shares

* Says it will repurchase up to 50 million shares, representing 2.4 percent of outstanding

Select another date: